

# FOXN1 compound heterozygous mutations cause selective thymic hypoplasia in humans

Qiumei Du, ... , M. Teresa de la Morena, Nicolai S.C. van Oers


J Clin Invest. 2019;129(11):4724-4738. <https://doi.org/10.1172/JCI127565>.

Research Article

Genetics

Immunology

## Graphical abstract



Find the latest version:

<https://jci.me/127565/pdf>



# FOXN1 compound heterozygous mutations cause selective thymic hypoplasia in humans

Qiumei Du,<sup>1</sup> Larry K. Huynh,<sup>1</sup> Fatma Coskun,<sup>1</sup> Erika Molina,<sup>1</sup> Matthew A. King,<sup>1</sup> Prithvi Raj,<sup>1</sup> Shaheen Khan,<sup>1</sup> Igor Dozmorov,<sup>1</sup> Christine M. Seroogy,<sup>2</sup> Christian A. Wysocki,<sup>3,4</sup> Grace T. Padron,<sup>5</sup> Tyler R. Yates,<sup>6</sup> M. Louise Markert,<sup>6,7</sup> M. Teresa de la Morena,<sup>8</sup> and Nicolai S.C. van Oers<sup>1,3,9</sup>

<sup>1</sup>Departments of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. <sup>2</sup>Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. <sup>3</sup>Department of Pediatrics, and <sup>4</sup>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. <sup>5</sup>University of Miami Miller School of Medicine, Miami, Florida, USA. <sup>6</sup>Department of Pediatrics and <sup>7</sup>Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA. <sup>8</sup>Division of Immunology, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, Washington, USA. <sup>9</sup>Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

**We report on 2 patients with compound heterozygous mutations in forkhead box N1 (FOXN1), a transcription factor essential for thymic epithelial cell (TEC) differentiation. TECs are critical for T cell development. Both patients had a presentation consistent with T<sup>-</sup>/B<sup>+</sup>NK<sup>+</sup> SCID, with normal hair and nails, distinct from the classic nude/SCID phenotype in individuals with autosomal-recessive FOXN1 mutations. To understand the basis of this phenotype and the effects of the mutations on FOXN1, we generated mice using CRISPR-Cas9 technology to genocopy mutations in 1 of the patients. The mice with the Foxn1 compound heterozygous mutations had thymic hypoplasia, causing a T<sup>-</sup>B<sup>+</sup>NK<sup>+</sup> SCID phenotype, whereas the hair and nails of these mice were normal. Characterization of the functional changes due to the Foxn1 mutations revealed a 5-amino acid segment at the end of the DNA-binding domain essential for the development of TECs but not keratinocytes. The transcriptional activity of this Foxn1 mutant was partly retained, indicating a region that specifies TEC functions. Analysis of an additional 9 FOXN1 mutations identified in multiple unrelated patients revealed distinct functional consequences contingent on the impact of the mutation on the DNA-binding and transactivation domains of FOXN1.**

## Introduction

The development of T cells expressing T cell receptors (TCRs) bearing a precise specificity for peptides embedded in self-HLA (MHC) molecules occurs in the thymus. At this site, T cell interactions with thymic epithelial cells (TECs) establish an individualized TCR repertoire. The developmental progression of T cells occurs in several stages and involves 2 distinct epithelial cell (EC) subsets, cortical and medullary TECs (1, 2). Designated by their distribution within the thymus, these subsets are functionally distinct despite developing from a common precursor cell (3). Cortical TECs (cTECs) support early T cell development. They release chemokines such as Ccl19, Ccl21, and Ccl25 to direct early thymocyte precursor entry at a cortical-medullary interface (4). cTECs also secrete IL-7, and in conjunction with the chemokines, combinatorially provide proliferation, differentiation, and directional information to the immature double-negative (DN) CD4<sup>+</sup>CD8<sup>-</sup> thymocyte subset (4). This is further determined by the expression on cTECs of delta ligand-like 4 (DDL4), which binds to Notch on immature thymocytes and leads to expression of the Notch-acti-

vated transcription factor RBPJ $\kappa$ . The various cTEC-dependent signals promote chromosome rearrangements at the TCR $\beta$  locus in the DN thymocytes. Successful expression of a TCR $\beta$  protein signals an expansion and differentiation phase of the DN cells into the double-positive (DP) CD4<sup>+</sup>CD8<sup>+</sup> subset. During this transition, the TCR $\alpha$  locus is rearranged, with a productively produced TCR $\alpha$  protein pairing with the TCR $\beta$  subunit. A byproduct of this rearrangement event is the TCR excision circle (TREC), which is the newborn screening analyte used to identify patients with SCID (5).

The survival of an  $\alpha\beta$  TCR-expressing DP thymocyte is enabled after favorable “weak” TCR interactions with self-peptides bound to MHC molecules presented by the cTECs (positive selection). The positively selected thymocytes are directed into the CD4<sup>+</sup>CD8<sup>-</sup> and CD4<sup>+</sup>CD8<sup>+</sup> single-positive (SP) subsets that enter the medullary regions. The expansion and function of medullary TECs (mTECs) relies on their crosstalk with SP thymocytes, with CD40L, RANKL, and EGF engaging CD40, RANK, and EGFR, respectively, on the TECs (6, 7). The mTECs present many tissue-restricted antigens on HLA molecules, a process that requires the transcriptional regulator termed AIRE, along with a second transcription factor, Fezf2 (8, 9). mTECs purge T cells with high-affinity, self-reactive TCR specificities (negative selection). An added function of mTECs is to support the selection of Tregs (10). The selected Tregs exit into the peripheral lymphoid organs, where they prevent the promiscuous activation of any remaining autoreactive T cells (11). The gauntlet of cTEC- and mTEC-mediated T cell selection processes, aided by DCs, results in pro-

**Conflict of interest:** MLM developed thymus transplantation intellectual property, which has been licensed to Enzyvant Therapeutics. Both MLM and Duke University may benefit financially if the technology is commercially successful in the future.

**Copyright:** © 2019, American Society for Clinical Investigation.

**Submitted:** January 25, 2019; **Accepted:** August 1, 2019; **Published:** September 30, 2019.

**Reference information:** *J Clin Invest.* 2019;129(11):4724–4738.

<https://doi.org/10.1172/JCI127565>.

**Table 1. Clinical presentations of 2 patients identified with compound heterozygous *FOXN1* mutations**

	Age	ALC (cells/ $\mu$ L)	CD3 <sup>+</sup> (cells/ $\mu$ L)	CD4 <sup>+</sup> (cells/ $\mu$ L)	CD8 <sup>+</sup> (cells/ $\mu$ L)	CD4 <sup>+</sup> , CD45RA <sup>+</sup> (cells/ $\mu$ L)	CD4 <sup>+</sup> , CD45RA <sup>+</sup> CD62L <sup>+</sup> (cells/ $\mu$ L)	NK (cells/ $\mu$ L)	CD19 <sup>+</sup> (cells/ $\mu$ L)	Mitogen proliferation
Reference range (40)	0–3 mo	3400–7600	2500–5500	1600–4000	560–1700	1200–3700	1200–3600	170–1100	300–2000	Normal PHA response >75,000 cpm
	6–12 mo	3400–9000	1900–5900	1400–4300	500–1700	1100–3700	1100–3600	160–950	610–2600	
Pt. 1	Day 17	1149	5	3	<1	–	3	533	575	Absent
	3 mo	2406	31	20	3	–	3	188	2159	–
	6 mo	1951	20	11	4	–	1	60	1849	–
	10 mo	996	91	51	18	–	15	120	741	–
	12 mo	1141	228	71	74	–	2	87	810	–
Pt. 2	Day 25	2290	137	115	0	2	–	939	1168	–
	Day 51	1740	122	104	17	2	–	505	1079	–
	~2 mo	–	–	–	–	–	–	–	–	Abnormal <sup>A</sup>
	~2 mo	–	–	–	–	–	–	–	–	Normal <sup>A</sup>
	Day 81	1650	79	73	3	–	10	–	–	Normal <sup>A</sup>

<sup>A</sup>The proliferation assays were conducted in 3 different laboratories; the initial mitogen proliferation used anti-CD3, anti-CD28, and anti-IL-2 stimulation, whereas the subsequent 2 assays were performed using phytohemagglutinin stimulation at 2 separate laboratories. ALC, absolute lymphocyte count; PHA, phytohemagglutinin.

grammed cell death for the vast majority of thymocytes. What emerges from the thymus is a population of mature T cells with a precise TCR specificity unique to a given individual.

The development and differentiation of TECs into the cortical and medullary subsets are established by the transcription factor forkhead box N1 (*FOXN1*) (1, 12). *FOXN1* belongs to a large family of proteins defined by a conserved, 100-amino-acid-long DNA-binding domain called the forkhead or winged helix. Forkhead family members are present in species from yeast to humans, but not in plants (13, 14). *FOXN1* arose via duplication of *FOXN4*, an ancestral homolog that first appeared in those early chordates with evidence of a thymus (1, 15, 16). Comprising 3  $\alpha$  helices, 3  $\beta$  sheets, and 2 loops designated as the wings, the third  $\alpha$  helix of *FOXN1* contacts the major groove of DNA (17). The second winged segment provides additional binding specificity within the minor groove of DNA. Foxn1 interacts with DNA sequences containing a GAa/cGC consensus and transcriptionally activates nearly 500 genes including keratins, cytokeratins, proteasome components, and cell-surface proteins (2). A transactivation domain near the COOH-terminal half of the protein is also required for Foxn1 functions (18).

The importance of *FOXN1* in TEC and keratinocyte development was first uncovered in a spontaneously arising nude phenotype in mice (*nu/nu*), which was later shown to be caused by autosomal-recessive mutations in this gene (12, 19). The loss of Foxn1 protein expression results in a TEC deficiency in combination with structural defects of the hair shaft and nail beds (12, 20, 21). This is the basis of the T<sup>B</sup><sup>+</sup>NK<sup>+</sup> nude/SCID phenotype. Since the original description of nude mice in 1966 and later, of nude rats, 3 distinct autosomal-recessive mutations in human *FOXN1* have been reported in approximately 10 patients, all of whom presented with similar nude/SCID phenotypes (22–26). This phenotype is also described in Birman cats (27). The classic clinical presentations for humans with autosomal-recessive *FOXN1* mutations include a T<sup>B</sup><sup>+</sup>NK<sup>+</sup> SCID phenotype due to thymic aplasia in conjunction

with alopecia universalis and nail plate dystrophy (23, 25, 28). Thymic hypoplasia/aplasia arising from defects with stromal cell populations such as TECs can also occur in individuals with mutations in *CHD7*, *PAX1*, *TBX1*, and *TBX2*, and in those with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome) (29–35). However, only the autosomal-recessive mutations described for *FOXN1* lead to the additional developmental problems of the hair shaft and nail plate.

We report here on the identification of mutations in *FOXN1* in 2 patients with a T<sup>+</sup>/B<sup>+</sup>NK<sup>+</sup> SCID without evidence of alopecia or nail dystrophy. We used CRISPR-Cas9 technology to develop *Foxn1* compound heterozygous mice that genocopied selected human *FOXN1* mutations. A comparison of the various mice harboring homozygous and compound heterozygous *Foxn1* mutations revealed differential functions of this transcription factor in TECs versus keratinocytes. Phenotype analyses and functional assays revealed an important 5-amino acid sequence in *Foxn1* that differentiates its role in TECs versus keratinocytes. A comparative analysis of 12 distinct *FOXN1* mutations, identified in patient 1 (Pt. 1) and patient 2 (Pt. 2) as well as in several unrelated patients with heterozygous mutations, revealed varying transcriptional activities depending on the location and type of mutation. These findings provide structure-function insights into this key transcription factor.

## Results

*Compound heterozygous mutations in FOXN1 identified in 2 unrelated patients with a SCID phenotype without alopecia.* Pt. 1 was a female born at full term to nonconsanguineous parents and was identified as having SCID following newborn screening that revealed undetectable TRECs. The subsequent clinical work-up was consistent with a typical T<sup>B</sup><sup>+</sup>NK<sup>+</sup> SCID phenotype, using the normal age-matched reference range (Table 1) (36, 37). Exome sequencing revealed 2 mutations in the *FOXN1* gene, a duplication

**Table 2. Clinical presentations of patients with compound heterozygous or monoallelic mutations in *FOXN1***

Patient	DNA mutation	Protein-coding mutation	Protein function (% of WT) (luciferase assay)	Abnormal hair	Abnormal nails	Transplant	Other clinical notes
Normal	None	None	100%	–	–	–	–
Pt. 1	c.933_936dupACCC	p.T313fsX169	1.5%	No	No	No	Multiple viral infections, failure to thrive. Died at 1 yr of age from parainfluenza virus.
Pt. 1	c.1089_1103del15	p.W363C	31%	No	No	No	Multiple viral infections, failure to thrive. Died at 1 yr of age from parainfluenza virus.
Pt. 2	c.1288C>T	p.P430S	100%	No	No	Yes	Received BM transplant. Healthy, no recurrent infections, on s.c. gamma globulin therapy.
Pt. 2	c.1465delC	p.R489fsX61	18%	No	No	Yes	Received BM transplant. Healthy, no recurrent infections, on s.c. gamma globulin therapy.
Pt. 3	c.1465delC	p.R489fsX61	18%	No	No	No	Healthy, no recurrent infections.
Pt. 4	c.1465delC	p.R489fsX61	18%	Yes	No	No	Healthy, no recurrent infections.
Pt. 5	724C>T	p.P242S	95%	No	No	No	Developed <i>S. aureus</i> submandibular abscess in infancy; otherwise healthy.
Pt. 6	958C>T	p.R320W	2%	No	No	No	Healthy, no recurrent infections.
Pt. 7	962A>G	p.H321R	82%	Yes	Yes	No	Died in infancy from coronavirus encephalitis. Also had a heterozygous <i>DOCK8</i> mutation.
Pt. 8	982T>C	p.C328R	16%	No	No	No	Healthy, no recurrent infections.
Pt. 9	1075G>A	p.E359K	63%	No	No	No	Healthy, no recurrent infections.
Pt. 10	1201_1206del16	p.P401AfsX144	3%	No	No	No	Also had heterozygous <i>DOCK8</i> and <i>CHD7</i> mutations with no congenital anomalies.
Pt. 11	1201_1206del16	p.P401AfsX144	3%	No	No	No	Healthy, no recurrent infections.
Pt. 12	1201_1206del16	p.P401AfsX144	3%	No	No	No	Healthy, no recurrent infections. Received live virus vaccines.
Pt. 13	1201_1206del16	p.P401AfsX144	3%	No	Yes	No	Healthy, no recurrent infections.
Pt. 14	1201_1206del16	p.P401AfsX144	3%	No	No	No	Born prematurely due to maternal infection. Currently healthy with no recurrent infections.
Pt. 15	1293delC	p.P432fsX118	2%	No	No	Yes	Low numbers through ~3 mo when alternate therapy was given.
Pt. 16	1418delC	p.P473HfsX77	12%	Yes	Yes	Yes	Low numbers through ~4 mo when alternative therapy was given.

*S. aureus*, *Staphylococcus aureus*.


of ACCC at position c.933 (c.933\_936dup), and a 15-nt deletion (c.1089\_1103del) (Table 2). Analysis of the parental data indicated that the 933 mutation was inherited from the mother, whereas the 1089 mutation was passed down from the father. Both parents were healthy and had no evidence of hair loss or nail changes (Figure 1, A, C, and D; Family 1). The c.933 duplication was identified as a presumed pathogenic variant that was predicted to result in a premature stop codon following a new coding sequence of approximately 169 amino acids extending from the middle of the DNA-binding domain (p.Thr313fs\*169). The second allele in Pt. 1 contained a 15-nt deletion near the end of the DNA-binding domain. This resulted in a single amino acid conversion (Trp to Cys) followed by a 5-amino acid deletion (p.Trp363\_Pro367delinsCys) (Figure 1, A and C). The deletion did not change the reading frame. The clinical course for Pt. 1 was characterized by rhino/enteroviral infection at 2 months of age, norovirus enteritis and failure to thrive starting at 5 months, and parainfluenza virus type 3 (PIV3) at 9 months (Table 2). Although this infant was a candidate for allogeneic thymic tissue transplantation, the recurring viral infections resulted in her death before 1 year of age. This was a consequence of respiratory failure with disseminated PIV3, with identification of the virus also in liver biopsies.

Pt. 2, born to nonconsanguineous parents, also had undetectable TRECs following newborn screening. Serial immune testing was consistent with a T<sup>+/0</sup>B<sup>+</sup>NK<sup>+</sup> leaky SCID phenotype with

persistent severe T cell lymphopenia, absent thymopoiesis, and diminished T cell function (Table 1). This child underwent hematopoietic cell transplantation at 6 months of age (Table 2). Exome sequencing revealed c.C1288T and c.1465delC *FOXN1* variants (Figure 1, B and E; family 2). Sanger sequencing confirmed individual *FOXN1* allelic mutations in Pt. 2. The nucleotide changes caused a p.Pro430Ser on FOXN1 derived from 1 allele and a p.Gln489Argfs on the second allele that resulted in a frameshift mutation in the protein (Figure 1, B, C, and E). The 1288 variant is a polymorphism found in 4% of the general population (dbSNP: rs61749867), but the impact of this variant on *FOXN1* has not been established. Analysis of the parents indicated that the c.C1288T variant was inherited from the mother, whereas the c.1465delC variant was de novo.

The *FOXN1* mutations described for both Pt. 1 and Pt. 2 are distinct from the classic autosomal-recessive mutations originally identified in *FOXN1* (Figure 1C) (22–26). To date, previously identified mutations on other genes associated with SCID or cellular immunodeficiency phenotypes were not found in Pt. 1 or Pt. 2 (Table 2).

*Mice harboring compound heterozygous mutations in Foxn1 have thymic hypoplasia with normal fur and nail beds.* To confirm that the *FOXN1* mutations in Pt. 1 were causal to the SCID phenotype, we used a CRISPR-Cas9 strategy to create analogous mutations in C57Bl/6 mice. Individual guide RNAs were designed with Cas9 cleavage sites near the equivalent positions in the murine locus




**Figure 1. Compound heterozygous mutations in *FOXN1* identified in 2 patients.** (A and B) Pt. 1 and Pt. 2 were identified from 2 independent and unrelated families. (C) Domain structure of *FOXN1*, with the 2 domains characterized to date: a DNA-binding region in the middle of the protein and a transactivation domain near the COOH terminus. Three *FOXN1* autosomal-recessive mutations previously reported in patients with nude/SCID phenotypes are listed in red. Two patients, Pt. 1 and Pt. 2, presented with compound heterozygous mutations in *FOXN1* at distinct sites, which are indicated above the exon assembly. (D and E) The DNA sequence mutations in *FOXN1* and the corresponding effects on the amino acid sequence are shown for Pt. 1 (D) and Pt. 2 (E). The amino acid changes resulting from the various *FOXN1* mutations are illustrated.

for Pt. 1, at positions 933 and 1089 (Figure 2A). Silent mutations were included to create new DNA restriction sites for genotyping purposes. The more difficult design was for position 933 (Pt. 1). At this location, the 4-nt duplication (ACCC) in human *FOXN1* creates a frameshift that begins mid-way through the DNA-binding domain. The corresponding TCCT insertion within the same location in the murine *Foxn1* locus creates an immediate stop codon. Consequently, a TCCC insertion was engineered into the murine locus along with several additional nucleotide substitutions within the repair template to better mimic the read-through seen with the patient's allele. The resulting coding sequences for both the human and murine genes following the insertion site were novel, with a new stop codon introduced within exon 6. The corresponding mutations in the human genome led to a longer transcript, again with codons unrelated to WT *FOXN1*.

The phenotypes of the founder pups derived from the CRISPR-Cas9 genome editing of the *Foxn1* 933-nt position were distinct from those targeted at position 1089. Many of the 933 pups had a nude, runted phenotype (Supplemental Figure 1A; supple-

mental material available online with this article; <https://doi.org/10.1172/JCI127565DS1>). DNA sequencing of these runs revealed deletions within the DNA-binding domain on both *Foxn1* alleles. In contrast, the 1089 founders appeared visually indistinguishable from normal mice (Figure 2B and Supplemental Figure 1A). Founders with the correct nucleotide duplication (933 nt) or deletion (1089 nt) in *Foxn1* were bred with WT mice, followed by intercrossing of the mice to establish the appropriate homozygous and compound heterozygous lines.

F2-generation mice homozygous for the 933 mutation (*Foxn1*<sup>933/933</sup>) were small and hairless and had diminished nail lengths and shortened whiskers compared with littermate controls (Figure 2B and Supplemental Figure 1B). These phenotypes matched that of the classic *nu/nu* mouse (12). In contrast, the physical appearance of the *Foxn1*<sup>1089/1089</sup> and *Foxn1*<sup>933/1089</sup> mice matched that of their littermate controls (Figure 2B). The *Foxn1*<sup>933/933</sup> mice had thymic aplasia, with a 35- to 50-fold reduction in thymus weights compared with littermate control thymus weights (Figure 2, C and D). The *Foxn1*<sup>1089/1089</sup> and *Foxn1*<sup>933/1089</sup> compound hetero-




**Figure 2. Human *FOXN1* compound heterozygous mutations genocoped in mice cause thymic aplasia with normal fur and nails. (A)** The human *FOXN1* mutations for Pt. 1 were introduced into the murine genome by CRISPR-Cas9 technology. The DNA repair template used for each allele is shown. Silent mutations were introduced into the murine sequence to facilitate genotyping and to prevent premature stop codons. **(B)** Images of F2-generation mice: WT *Foxn1* (*Foxn1*<sup>WT/WT</sup>), homozygous mutant (*Foxn1*<sup>933/933</sup> and *Foxn1*<sup>1089/1089</sup>), and compound heterozygous (*Foxn1*<sup>933/1089</sup>) mice, the latter genocopying Pt. 1. The genocoped mice are indicated in red font. The images are representative of 5 independently characterized mice. **(C)** The overall sizes of the thymi from the various mouse lines are shown for comparative purposes. **(D)** Thymus weights and overall thymic cellularity were calculated. Data represent the mean  $\pm$  SEM.  $n = 22$  *Foxn1*<sup>WT/WT</sup>,  $n = 6$  *Foxn1*<sup>933/933</sup>,  $n = 10$  *Foxn1*<sup>1089/1089</sup>, and  $n = 10$  *Foxn1*<sup>933/1089</sup> mice.  $P$  values of less than 0.05 were considered significant. For the comparisons shown, a Brown-Forsythe and Welch's 1-way ANOVA was applied.

zygous mice had pronounced thymic hypoplasia, with a 10- and 17-fold reduction in thymus weights, respectively (Figure 2, C and D). This was confirmed when we compared the total thymic cellularity of 6 to 22 mice per group (Figure 2D). Sex was not a determinant for the hypoplasia, as males and females were equally affected (Supplemental Figure 2A). A comparison of the various heterozygous mice derived from the intercrosses (*Foxn1*<sup>WT/1089</sup> and *Foxn1*<sup>WT/933</sup>) revealed no impact of a single-allele mutation on thymic cellularity, T cell development, and/or peripheral lymphocytes compared with littermate controls (Supplemental Figure 2, B–E). These findings firmly establish that the clinical phenotypes of Pt. 1 resulted from compound heterozygous mutations in *FOXN1*.

*Thymopoiesis is severely attenuated in mouse lines with compound heterozygous mutations in Foxn1 that genocopy Pt. 1.* To understand


how the diverse *FOXN1* mutations affect thymopoiesis, we compared the developmental progression of thymocytes in the different mouse lines (Figure 3A). We monitored the various stages by comparing the cell-surface expression of the CD4, CD8, TCR $\beta$ , CD25, CD44, CD45, and CD69 by flow cytometry. As shown in the littermate controls (*Foxn1*<sup>WT/WT</sup>), thymopoiesis was characterized by a subset of immature CD4<sup>+</sup>CD8<sup>-</sup> cells (DN, 4%) that developed into a CD4<sup>+</sup>CD8<sup>+</sup> cell population (DP, 80%–87%), of which a small number were positively selected into the CD4<sup>+</sup>CD8<sup>-</sup> (CD4 SP, 3%–8%) and CD4<sup>-</sup>CD8<sup>+</sup> lineages (CD8 SP, 2%–5%) (Figure 3A). With the exception of some DN and CD8<sup>lo</sup> cells, the DP and SP cell populations were virtually nonexistent in the *Foxn1*<sup>933/933</sup> mouse line (Figure 3A). The DN and CD8<sup>lo</sup> cell populations lacked CD45<sup>+</sup> cell-surface expression, indicating that they were not thy-



**Figure 3. Thymic hypoplasia results from compound heterozygous mutations in *Foxn1*.** (A–D) WT *Foxn1* (*Foxn1*<sup>WT/WT</sup>), homozygous mutant (*Foxn1*<sup>933/933</sup>, *Foxn1*<sup>1089/1089</sup>), and compound heterozygous (*Foxn1*<sup>933/1089</sup>) mice, the latter genocopying Pt. 1, were obtained by intercrossing the *Foxn1*<sup>933/WT</sup> and *Foxn1*<sup>1089/WT</sup> lines. The thymus was isolated and single-cell suspensions prepared for flow cytometry. (A) Fluorescence-labeled antibodies against CD4 and CD8 were used to detect DN, DP, and SP thymocyte subsets. (B) The progression of thymocytes from the DN1–DN4 stages of thymocytes was assessed by cell-surface staining for CD44 and CD25 following exclusion of cells expressing CD3, CD4, CD8, B220, NK1.1, TCRγδ, Ter199, CD11b, and CD11c. (C) Positive selection of thymocytes was assessed by staining thymocytes for TCRβ and CD69. (D) Graphs show the percentage of various cell subsets, determined from pooled experiments using a minimum of 5 mice per line. Data indicate the mean ± SEM. *n* = 22 *Foxn1*<sup>WT/WT</sup> mice, *n* = 6 *Foxn1*<sup>933/933</sup> mice, *n* = 6 *Foxn1*<sup>1089/1089</sup> mice, and *n* = 5 *Foxn1*<sup>933/1089</sup> mice. For the comparisons shown, a Brown-Forsythe and Welch’s 1-way ANOVA was applied. *P* values of less than 0.05 were considered significant. \*\*\*\**P* < 0.0001 for most comparisons, with the following exceptions: *P* = 0.002 for DN comparisons of *Foxn1*<sup>933/933</sup> versus *Foxn1*<sup>1089/1089</sup>; *P* = NS for DP comparisons of *Foxn1*<sup>WT/WT</sup> versus *Foxn1*<sup>1089/1089</sup> and *Foxn1*<sup>933/933</sup> versus *Foxn1*<sup>933/1089</sup>; *P* = 0.002 for CD4<sup>+</sup> SP *Foxn1*<sup>933/933</sup> versus *Foxn1*<sup>1089/1089</sup> and *Foxn1*<sup>1089/1089</sup> versus *Foxn1*<sup>933/1089</sup>; *P* = NS for *Foxn1*<sup>933/933</sup> versus *Foxn1*<sup>933/1089</sup>; *P* = 0.05 for CD8<sup>+</sup> SP *Foxn1*<sup>933/933</sup> versus *Foxn1*<sup>933/1089</sup>. Comparisons for DN1–DN4 were as follows: *P* = NS for DN1 differences between *Foxn1*<sup>WT/WT</sup> and *Foxn1*<sup>1089/1089</sup>; *P* = 0.008 for DN2 comparisons of *Foxn1*<sup>WT/WT</sup> versus *Foxn1*<sup>1089/1089</sup>, *P* = 0.002 for DN2 comparisons of *Foxn1*<sup>933/933</sup> versus *Foxn1*<sup>1089/1089</sup>, and *P* = NS for DN2 comparisons of *Foxn1*<sup>1089/1089</sup> versus *Foxn1*<sup>933/1089</sup>; *P* = 0.002 for DN3 comparisons of *Foxn1*<sup>933/933</sup> versus *Foxn1*<sup>1089/1089</sup> and *P* = NS for DN3 comparisons of *Foxn1*<sup>WT/WT</sup> versus *Foxn1*<sup>1089/1089</sup>; *P* = 0.002 for DN4 comparisons of *Foxn1*<sup>933/933</sup> versus *Foxn1*<sup>933/1089</sup> and *P* = NS for DN4 comparisons of *Foxn1*<sup>WT/WT</sup> versus *Foxn1*<sup>1089/1089</sup>. ND, not detected; PE, phycoerythrin.

mocytes (Figure 3A, data not shown). This finding concurs with the cystic thymic rudiment described for the *nu/nu* mice, which was devoid of thymocytes (38). The *Foxn1*<sup>1089/1089</sup> homozygous knockin mice had an increased percentage of DP thymocytes (90%–95%) with severely reduced SP subsets compared with controls. Such results suggest that homozygous mutations at the 1089 position of *Foxn1* lead to some differentiation of thymocytes to the CD4<sup>+</sup>CD8<sup>+</sup> stage, at which point there was a developmental block. Thymopoiesis in the *Foxn1*<sup>933/1089</sup> mice, genocopying Pt. 1, was more severely affected. A significant reduction in the percentage of both DP and SP subsets was obvious, albeit not as extreme as that seen in the *Foxn1*<sup>933/933</sup> mouse line, a finding consistent with the presence of a small thymic structure (Figure 2C). These data confirm that the distinct *Foxn1* mutations have dif-

ferential consequences for early T cell development and positive selection. We further explored this by characterizing the 4 stages of DN thymocyte progression as DN1–DN4 (DN1: CD44<sup>+</sup>CD25<sup>-</sup>, DN2: CD44<sup>+</sup>CD25<sup>+</sup>, DN3: CD44<sup>-</sup>CD25<sup>+</sup>, DN4: CD44<sup>-</sup>CD25<sup>-</sup>). We noted similar percentages of each of the DN1–DN4 subsets when we compared *Foxn1*<sup>1089/1089</sup> thymocytes with those of normal controls (Figure 3B). However, the mouse line that genocopied Pt. 1 (*Foxn1*<sup>933/1089</sup>) had a selective block at the DN1 stage (Figure 3B). The sparse cells in the *Foxn1*<sup>933/933</sup> line were mainly CD45<sup>-</sup>, revealing a severe lack of immature DN thymocytes. We assessed the effect on positive selection by screening for the upregulation of CD69 on cells expressing intermediate levels of TCRβ (Figure 3C). The percentage of CD69<sup>+</sup> thymocytes expressing intermediate or high levels of the TCRβ subunit was reduced in the *Foxn1*




**Figure 4. Mice with compound heterozygous mutations in *Foxn1* have severe peripheral T cell lymphopenia.** (A–C) Lymph nodes were collected from the indicated mice and stained with antibodies detecting cell-surface CD4, CD8, B220, TCRβ, and NK1.1 expression. The cells were analyzed by flow cytometry comparing the cell-surface expression of (A) CD4<sup>+</sup> and CD8<sup>+</sup> SP cells; (B) B220 (marker of B cells) and CD3ε cell-surface expression; and (C) NK1.1 cell-surface expression and TCRβ. *n* = 3 to 26 mice per genotype for A–C. APC, allophycocyanin. (D) The percentages of CD4<sup>+</sup> SP cells, CD8<sup>+</sup> SP cells, B220<sup>+</sup> B cells, and CD3ε<sup>+</sup> T cells were calculated; *n* = 24 *Foxn1*<sup>WT/WT</sup>, *n* = 5 *Foxn1*<sup>933/933</sup>, *n* = 11 *Foxn1*<sup>1089/1089</sup>, and *n* = 21 *Foxn1*<sup>933/1089</sup> mice. The percentages of NK1.1<sup>+</sup> TCRβ<sup>+</sup> cells were calculated; *n* = 26 *Foxn1*<sup>WT/WT</sup>, *n* = 3 *Foxn1*<sup>933/933</sup>, *n* = 11 *Foxn1*<sup>1089/1089</sup>, and *n* = 11 *Foxn1*<sup>933/1089</sup> mice. For the comparisons shown, a Brown-Forsythe and Welch’s 1-way ANOVA was applied. *P* values of less than 0.05 were considered significant.

heterozygous mouse line (*Foxn1*<sup>933/1089</sup>) and in one of the homozygous mutant lines (*Foxn1*<sup>1089/1089</sup>) (Figure 3C). These developmental abnormalities were of statistical significance, as revealed by comparisons of the different thymocyte subpopulations with multiple mice per group (Figure 3D).

The consequence of the thymic aplasia (*Foxn1*<sup>933/933</sup> mice) and hypoplasia (*Foxn1*<sup>1089/1089</sup> and *Foxn1*<sup>933/1089</sup> lines) is an almost complete loss of mature CD4<sup>+</sup> and CD8<sup>+</sup> SP T cells in the peripheral lymph nodes of these mice (Figure 4A). B cells and NK cells were present, confirming the T<sup>B</sup> NK<sup>+</sup> SCID phenotype of Pt. 1 (Figure

4, B–D). Comparison of the cell populations using 3–26 mice per group confirmed the statistical significance of the findings (Figure 4D). The various cell populations in 6-week-old heterozygous mice (*Foxn1*<sup>WT/933</sup> and *Foxn1*<sup>WT/1089</sup>) were similar to normal control cell populations, revealing that 1 functional allele of *Foxn1* was sufficient to support normal T cell development (Supplemental Figure 2, B–E). Taken together, our data demonstrate that T cell development is severely compromised in mice with compound heterozygous mutations in *Foxn1* matching Pt. 1 and results in severe T cell lymphopenia.






**Figure 5. The thymic architecture is severely disrupted in mice with homozygous and compound heterozygous *Foxn1* mutations that genocoped Pt. 1.** (A) Thymi were isolated from mice of the indicated genotypes (32–45 days old) and processed for H&E staining. Sections are shown at different magnifications to illustrate the severe thymic aplasia in the *Foxn1*<sup>933/933</sup> and *Foxn1*<sup>933/1089</sup> genotypes. Scale bars: 1 mm. (B) IHC was performed on thymic tissue sections with antibodies detecting cTECs (cytokeratin 8) and mTECs (cytokeratin 5). Two independent tissue samples were used per genotype and were labeled as the first set and second set. Scale bars: 0.5 mm. (C) Dispersed thymic tissues were prepared from mice of the indicated genotypes, and TECs were compared by flow cytometry, first by gating on EpCAM<sup>+</sup>CD45<sup>-</sup> cells with antibodies detecting cTECs (BP-1) and mTECs (UEA-1) along with the cell-surface levels of MHC CII. (D and E) mTEC populations (UEA-1) were costained with antibodies detecting MHC CII in mice of the indicated genotypes, and dot blot comparisons are shown. (E) The MHC CII expression was compared between control littermates (black line) and *Foxn1*<sup>1089/1089</sup> mice (gray line). (F) The percentage of the different cTEC and mTEC subsets in the thymus of the indicated mice was calculated (*n* = 4 mice/group). Statistical analysis was performed using a Student's *t* test.

*Cortical and medullary TECs are affected by mutations in Foxn1.* In the thymus, *Foxn1* expression is restricted to ECs. To determine how the diverse *Foxn1* mutations impact TECs, we compared cTEC and mTEC subsets. H&E staining of the tissue in the *Foxn1*<sup>933/933</sup> and *Foxn1*<sup>933/1089</sup> lines revealed hypoplastic/aplastic tissue with poorly defined cortical and medullary segments, cystic regions, and increased adipose tissue (Figure 5A). Immunofluorescent staining with antibodies specific for cTECs (cytokeratin 8

and mTECs (cytokeratin 5) revealed an almost complete absence of these cells in *Foxn1*<sup>933/933</sup> and *Foxn1*<sup>933/1089</sup> mice relative to what we observed in the littermate controls (Figure 5B). Thymi from the *Foxn1*<sup>1089/1089</sup> line were not as severely affected, as small clusters of cTECs and mTECs were evident in the hypoplastic tissue. The number and percentage of cTECs and mTECs in these mice relative to littermate controls were determined by flow cytometry (Figure 5C). With regard to cell percentages, the *Foxn1*<sup>WT/WT</sup> mice had




**Figure 6. Functional impairment of Foxn1 is dependent on the location and type of mutation.** (A–C) Transient transfection assays in HEK293T cells were performed with expression vectors for WT *Foxn1* or *Foxn1* constructs harboring the indicated mutations that matched the *FOXN1* mutations identified in patients. The mutations were divided into those identified in Pt. 1 (A) (*Foxn1*<sup>933</sup>, *Foxn1*<sup>1089</sup>) and Pt. 2 (B) (*Foxn1*<sup>1288</sup>, *Foxn1*<sup>1465</sup>) as well as the indicated controls. Forty-eight hours after transfection, the cells were lysed, and the proteins were extracted and resolved by SDS-PAGE. Western blotting was performed with antibodies against Foxn1, followed by antibodies detecting GAPDH, which was used as a loading control. Blots are representative of 4 independent experiments. (C and D) HEK293T cells were transfected with the indicated constructs along with a *Psmb11* luciferase reporter construct and a  $\beta$ -gal vector. The mutations (*mFoxn1*) were grouped for those identified in Pt. 1 (C) (*Foxn1*<sup>933</sup>, *Foxn1*<sup>1089</sup>) and Pt. 2 (D) (*Foxn1*<sup>1288</sup>, *Foxn1*<sup>1465</sup>) along with controls (D). Forty-eight hours after transfection, the cells were harvested, and luciferase activity was measured. The luciferase activity was normalized to  $\beta$ -gal, which was used as an internal control. Data are representative of triplicate samples from each group using 3 independent transfections per group. *P* values were determined using a standard 1-way ANOVA.

approximately 13% and 81% cTECs and mTECs (EpCam<sup>+</sup>CD45<sup>-</sup>), respectively (Figure 5, C and F). In contrast, the *Foxn1*<sup>1089/1089</sup> thymi had 4% and 31% cTEC and mTEC representation, respectively (Figure 5F). The lower percentages in the *Foxn1*<sup>1089/1089</sup> mice were matched with an increased percentage of EpCam<sup>+</sup>CD45<sup>-</sup> TECs from the *Foxn1*<sup>1089/1089</sup> mouse line (62%), which lacked the cytokeratin markers that distinguish cTECs and mTECs (Figure 5C). In normal mice, the mTECs were divided into the less mature MHC class II<sup>lo</sup> (MHC CII<sup>lo</sup>) and more mature MHC class II<sup>hi</sup> (MHC CII<sup>hi</sup>) cells (Figure 5, D and E). We detected a significant reduction in the percentage of MHC CII<sup>hi</sup> cells in the *Foxn1*<sup>1089/1089</sup> lines, and the MHC CII<sup>+</sup> cells present had a reduced cell-surface expression of this molecule relative to littermate controls (Figure 5, D and E). These TEC comparisons indicate that the mutations at the 1089 position of *FOXN1* are not as damaging as those that disrupt the DNA-binding domain (position 933), providing some functionality for TEC development.

The transcriptional activity of *Foxn1* is regulated by both the DNA-binding and transactivation domains. To determine how the distinct *FOXN1* mutations identified in Pt. 1 and Pt. 2 affect the expression and function of the protein, we introduced substitutions or deletions into the cDNA of murine *Foxn1* and performed protein expression and promoter-based reporter assay comparisons (2, 39). The insertion of the 4-nt sequence identified in Pt. 1 (*Foxn1*<sup>933</sup>) resulted in the expression of a truncated 50-kDa protein (Figure 6A). The 15-nt deletion, corresponding to the one identified in the second allele of Pt. 1 (*Foxn1*<sup>1089</sup>), was almost identical in molecular mass to that of the WT control (Figure 6A). *Foxn1*<sup>1288</sup> was also similar in size to *Foxn1*<sup>WT</sup>, whereas a single nucleotide deletion at position 1465 created a truncated protein with a mass of 65 kDa as a result of the frameshift (Figure 6B). As our studies were progress-

ing, several additional *FOXN1* mutations were identified in unrelated patients presenting with low T cell counts for whom exome sequencing was undertaken (Table 2 and Supplemental Table 1). Unlike the compound heterozygous genotypes for Pt. 1 and Pt. 2, these patients had *FOXN1* mutations evident only on a single allele (Table 2 and Supplemental Table 2). One subject had a previously reported R320W mutation in *FOXN1*, whereas 2 patients had the 1465delC that was noted in Pt. 2. We characterized *FOXN1* with SNPs (*FOXN1*<sup>724</sup>, *FOXN1*<sup>958</sup>, *FOXN1*<sup>962</sup>, *FOXN1*<sup>982</sup>, *FOXN1*<sup>1075</sup>) and deletions (*FOXN1*<sup>1201\_1216</sup>, *FOXN1*<sup>1293delC</sup>, *FOXN1*<sup>1418delC</sup>), with the human mutations introduced into the murine cDNA (Supplemental Table 2). Consistent with the location and type of mutation, either full-length or truncated Foxn1 proteins were expressed (Supplemental Figure 3, A and B).

The functional activity of *Foxn1* mutations corresponding to those in Pt. 1 and Pt. 2, along with the additional mutations, were compared by transcriptional reporter assays using the promoter sequence for the *Psmb11* gene, which encodes  $\beta$ 5t (2). We found that *Foxn1*<sup>933</sup> had virtually no transcriptional activity (Figure 6C). The *Foxn1* constructs with mutations at positions 1089 and 1465 had 31% and 18% WT activity, respectively (Figure 6D). Interestingly, coexpression of the corresponding heterozygous mutation (*Foxn1*<sup>1089</sup> with *Foxn1*<sup>933</sup>) or the polymorphism (*Foxn1*<sup>1288</sup> with *Foxn1*<sup>1465</sup>) did not attenuate the transcriptional activity of the functional allele, suggesting that Foxn1 functions as a monomer (Figure 6, C and D). *Foxn1*<sup>958</sup> was inactive, whereas *Foxn1*<sup>724</sup> and *Foxn1*<sup>962</sup> had activity comparable to that of *Foxn1*<sup>WT</sup>, at 95% and 82% normal values, respectively (Table 2 and Supplemental Figure 3C). *Foxn1*<sup>982</sup> and *Foxn1*<sup>1075</sup> exhibited 16% and 63% control activity, respectively (Table 2 and Supplemental Figure 3C). The deletions at positions 1201, 1293, and 1418 had a more severe effect,



**Figure 7. Differential functions of *Foxn1* in TECs versus keratinocytes.** (A) Gene expression comparisons were made with 3 independently isolated fetal thymi, obtained from E13.5 embryos of the indicated genotypes. The presence of a hypoplastic thymus was confirmed by subsequent genotyping to select for *Foxn1*<sup>933</sup> and *Foxn1*<sup>1089</sup> alleles. A heatmap revealed a subset of up- and downregulated genes, with a selection criterion of a 1.5-fold difference as a cut-off. (B) Data on differentially expressed transcripts, particularly those with reported functions in embryonic thymic development. (C) Images of postembryonic day-4 mice of the indicated genotypes were processed with bright-field imaging on a dark background, revealing hair and fur extending out from the skin. Scale bars: 1 mm. (D and E) qRT-PCR was performed to compare the levels of genes previously reported to be involved in hair shaft extension. This was performed to compare (D) 3 littermate controls and 3 *Foxn1*<sup>933/933</sup> mice and, in a separate experiment, (E) 3 controls and 3 *Foxn1*<sup>933/1089</sup> mice. The data shown reflect results from 1 of 2 independent experiments with 2 to 3 mice per group. \**P* = 0.02, \*\**P* = 0.001, and \*\*\*\**P* = 0.00006, by Student's *t* test. There were no significant differences in any of the transcripts compared between the 2 mouse lines in E.

reducing the functional activities of *Foxn1* to 3%, 2%, and 12% of normal values, respectively (Table 2 and Supplemental Figure 3D). Taken together, these results confirm crucial roles for both the DNA-binding and transactivation domains in the transcriptional activity of *Foxn1*, with the extent of functional incapacitation being dependent on the location and type of *Foxn1* mutation (Figure 1C and Table 2).

*FOXN1 differentially regulates genes in the thymus versus the skin.* The *Foxn1*<sup>933/933</sup> homozygous knockin mice have a phenotype

identical to that of the classic *nu/nu* mouse, consistent with an essential role for the *FOXN1* DNA-binding domain in both TEC and keratinocyte differentiation and gene expression. Contrasting with this, the *Foxn1*<sup>933/1089</sup>-knockin mouse line, genocopying Pt. 1, had a normal hair coat and whiskers despite the dramatic thymic hypoplasia. This suggests that the *Foxn1*<sup>933/1089</sup> mutations transcriptionally affect TECs differently than they do keratinocytes. We considered 2 explanations for the divergent consequences of harboring *Foxn1*<sup>933/933</sup> versus *Foxn1*<sup>933/1089</sup> genotypes for hair and nail

phenotypes. First, the *FOXN1*<sup>933/1089</sup> mutations could selectively affect the TEC transcriptome as opposed to the keratinocyte transcriptome. Alternatively, the loss-of-function mutations in *FOXN1* could modulate RNA transcripts in both TECs and keratinocytes in a quantitative manner, with the latter cell population maintaining reduced yet sufficient levels of transcripts to enable extrusion of the hair shaft and nail beds. To address these possibilities and characterize the transcript changes that resulted from the compound heterozygous mutations in *FOXN1*, we performed comparative gene expression analyses. RNA was extracted from embryonic thymic lobes at E13.5 and used for gene analyses. The E13.5 time point coincides with an expansion/differentiation phase of TECs prior to significant thymocyte expansion. We made gene expression comparisons with 3 control thymi (*Foxn1*<sup>WT/WT</sup>) and 3 hypoplastic thymi (*Foxn1*<sup>933/1089</sup>) (Figure 7A). Gene array comparisons revealed 417 upregulated and 500 downregulated genes in the *Foxn1*<sup>933/1089</sup> line relative to the littermate controls (Figure 7A). These differences were not surprising, given the severe hypoplasia evident in the *Foxn1*<sup>933/1089</sup> mice (Figure 3B). Our focus on a select subset of transcripts with roles in the development of the thymus and parathyroids, which are linked during the patterning of the third pharyngeal apparatus, revealed some surprising differences (Figure 7B). *Tbx1* and *Eya1* levels were higher in mutant mice, suggesting impaired differentiation of the thymus within the third pharyngeal pouch region (Figure 7B and Supplemental Table 3). In contrast to this, we found that *Pax1* and *Dcs2* levels were substantially lower in mutant mice (Supplemental Table 3). Although *Pax1* participates in the formation of the thymic lobes, *Dsc2* has only been described as a *Foxn1* target in the skin (3, 40). Taken together, our data are consistent with previous reports comparing normal and *Foxn1*-mutant mice and provide further insights into the transcript changes in embryonic hypoplastic thymi (2).

To determine how the same mutations in *Foxn1* affect hair follicle development, we isolated skin from 4-day-old pups. This is a stage when hair follicle extrusion and whisker formation is first evident in normal mice (Figure 7C). As previously reported, the *Foxn1*<sup>933/933</sup> pups showed no hair follicle extrusion (Figure 7C). In contrast, the hair in the *Foxn1*<sup>933/1089</sup> mice was visually similar to that of littermate controls (Figure 7C). We performed quantitative reverse transcription PCR (qRT-PCR) to compare a number of key genes expressed along the developing hair shaft needed for hair follicle extrusion. The nude mice (*Foxn1*<sup>933/933</sup>) had reduced expression of mouse *Krt84* (*mKrt84*), *mKrt33*, *mKrt33b*, and *mDsc2*, consistent with the central role of the DNA-binding activity of *Foxn1* in enabling keratinocyte functions (Figure 7D). *Foxn1*<sup>933/1089</sup> mice have no nude phenotype. The transcripts coupled to hair follicle extrusion in these mice were expressed at levels comparable to those seen in littermate controls (Figure 7E). This indicates a functional dichotomy in the requirements for *Foxn1* in controlling extrusion of the hair shaft in comparison with expression of thymus-selective genes.

## Discussion

*FOXN1* is a master transcriptional regulator of TECs that controls the expression of genes critical for both cTEC and mTEC differentiation and expansion (1, 28, 41). Although autosomal-recessive mutations in *FOXN1* can result in a nude/SCID phenotype, even hypomorphic alleles can reduce the effectiveness of thymopoiesis

(2, 42). This is best revealed in mouse models, in which enforced expression of *Foxn1* in aged mice prevents the characteristic age-related thymic involution and improves T cell output (43–45). We identified what to our knowledge are several previously unreported mutations in human *FOXN1* and, for 2 patients, distinct compound heterozygous mutations. Genocopying the compound heterozygous mutations identified in Pt. 1 using a mouse model was consistent with a novel clinical presentation of T<sup>+</sup>B<sup>+</sup>NK<sup>+</sup> SCID without evidence of alopecia or nail dystrophy. We identified the *FOXN1* variants in Pt. 2 using targeted exome sequencing. However, this approach did not establish whether both variants were restricted to 1 allele, with the possibility that a normal *FOXN1* sequence was present on the second allele. To answer this, we cloned the region comprising exon 8 and used more than 16 independently isolated bacterial clones to sequence the *FOXN1* region comprising positions 1288 and 1465. Consistent with a compound heterozygous genotype, we confirmed individual allelic variants for positions 1288 and 1465. We also had an unexpected finding of some clones with a WT *FOXN1* sequence. Although molecular analysis for maternal engraftment when the child was 2 months of age was negative, we suspect that the WT *FOXN1* sequences were maternally derived, since DNA was obtained from the child's blood at 5 months of age (subsequent studies for maternal engraftment were not obtained at this time point). Moreover, the mother did not have any clinical indications of a T<sup>-/lo</sup> phenotype. The allelic variant at position 1288 did not affect the expression or function of full-length *FOXN1*, as established through Western blot analysis and a  $\beta$ 5t luciferase reporter assay. The 1288 polymorphism is in fact reported in approximately 3% of the general population (dbSNP: rs61749867), suggesting that it is benign. However, the Pro-to-Ser amino acid change due to the 1288 polymorphism would result in a conformational modification in the protein. This change could affect *FOXN1* interactions with other proteins involved in thymopoiesis. Consequently, we cannot rule out the possibility that the 1288 variant has a functional impact in vivo in the context of a second allelic *FOXN1* pathogenic variant. We are currently testing this in additional mouse models.

Our characterization of the human *FOXN1* mutations in mouse models has uncovered what we believe to be a novel region at the COOH-terminal end of the DNA-binding domain that uncouples TEC development from keratinocyte differentiation. Comparison of the thymic hypoplasia in the *Foxn1*<sup>933/1089</sup> and *Foxn1*<sup>1089/1089</sup> mouse lines revealed a critical 5-amino acid stretch in *Foxn1* that was deleted as a result of the 1089 mutation in Pt. 1. This 5-amino acid segment is highly conserved with *Foxn4*, an ancestral gene present in all species that evolved with a thymus or thymus-like structure (thymoid) (Supplemental Figure 4) (16). The thymus/thymoid-like structures are present in cartilaginous fish (sharks) and agnathans (lampreys), but not in cephalochordates (segmented marine animals such as lancelets) (19). Interestingly, the 5-amino acid sequence in the lancelet *Foxn4* diverges from that in lamprey, potentially explaining the emergence of the thymus-like structure (16). Possible interactions between this 5-amino acid stretch and distinct transcription factors and/or other DNA-binding proteins could account for the differential function in TECs versus keratinocytes. Although one nuclear localization site (NLS) prediction program suggested that this site was an NLS, we noted that the

Foxn1<sup>1089</sup> protein could translocate into the nucleus. Further supporting our suggestion that the nuclear localization remains intact with the 15-nt deletion in Foxn1<sup>1089</sup> is the observation that the compound heterozygous mice (*Foxn1*<sup>933/1089</sup>) genocopying Pt. 1 had normal transcript levels of genes necessary for hair follicle extrusion. In most studies to date, *Foxn1* appears to have overlapping requirements for both TEC and keratinocyte development (46). To our knowledge, only 1 report has revealed a differential contribution of *Foxn1* in TECs versus keratinocytes (18, 47). In the published study, the removal of exon 3 selectively caused thymic aplasia, with no effects on hair shaft or nail bed development (47). It remains unknown how the exon 3 deletion results in the differential effects of Foxn1 on TECs versus keratinocytes.

A second important region in *Foxn1* is the transactivation domain, encoded within exons 8–9 (18). The compound heterozygous mutations in Pt. 1 are proximal to this transactivation domain. In addition, Pt. 2 presented with a mutation at 1465, which affects the transactivation domain. The introduction of this 1465 deletion mutation in murine *Foxn1* resulted in the expression of a truncated protein that had only 18% normal transcriptional activity, even though the DNA-binding domain remained intact. This confirms a critical role for the transactivation domain in TEC development, possibly via interactions with a yet-to-be identified coactivator. Alternatively, the mutations near the transactivation domain may provide additional DNA-binding specificity for induction of TEC-selective genes, and keratinocytes may not require this binding specificity.

Several additional patients were identified through SCID screening of newborns with low TREC numbers and were found to have mutations on just 1 allele of *FOXNI*. These mutations affected multiple regions in *FOXNI*, including the DNA-binding and/or transactivation domains (Table 2 and Supplemental Table 2). Although not predicted to be causal to a SCID phenotype because of the presence of 1 WT allele, such mutations could lead to reduced T cell output, either during stress at birth or through aging. In mouse models, hypomorphic mutations in murine *Foxn1* result in thymic involution as the mice age, contributing to reduced T cell output (42, 45, 48, 49). It remains to be seen whether patients with single-allele mutations in *FOXNI* have an earlier onset of thymic involution at birth due to stress and later in life. Although our comparisons of 24-week-old Foxn1 heterozygous mice (*Foxn1*<sup>933/WT</sup>) failed to reveal evidence of premature thymic involution, the impact of stress on thymopoiesis still needs to be assessed in these mice (50). Among the patients with single-allele mutations were 2 individuals with the same mutation as that in Pt. 2, at position 1465. Pt. 7 has a mutation in the DNA-binding region of *FOXNI* and was clinically reported to have very low T cell numbers and normal hair and nail beds. Such findings suggest that additional polymorphisms and/or mutations in noncoding regions of *FOXNI* (intron, promoter, enhancer elements) could contribute to the low T cell counts noted in those with only 1 affected allele. Alternatively, mutations in other genes coupled to *FOXNI* functions may further compound the effects of the identified single-allele mutations, as exemplified with the reported *DOCK8* and/or *CHD7* mutations in 2 of the patients (Table 2).

In summary, we describe what we believe to be a new clinical presentation of a primary immunodeficiency related to com-

pound heterozygous mutations in *FOXNI*, causing T<sup>-</sup>/B<sup>+</sup>NK<sup>+</sup> SCID without the typical nude phenotype. Therefore, a careful structure-function analysis is warranted before assuming that low TREC and T cell counts in patients are caused by *FOXNI* mutations, particularly in individuals with monoallelic mutations. Consideration of maternal T cell engraftment is also important if most of the cells are memory T cells and a low TREC output is maintained. A challenge is to know whether a given *FOXNI* mutation may allow for the development of sufficient numbers of T cells to prevent infections. Thymus transplantation should not be undertaken if the T cell numbers are likely to increase with time (51, 52). In view of the likelihood that the 2 alleles of *FOXNI* produce proteins that function independently, patients with single-allele mutations should be followed at least for several months to a year prior to considering thymus transplantation.

## Methods

**Antibodies, oligonucleotides, and plasmids.** The antibodies used in the experiments as well as their sources and the plasmids used for transfections are listed in Supplemental Table 4. Oligonucleotide sequences used for genotyping, PCR reactions, qRT-PCR reactions, and sequencing are listed in Supplemental Table 5. The murine *Foxn1* cDNA was cloned from genomic DNA using E14.5 fetal thymi isolated from C57BL/6 timed pregnant mice. The sequence was confirmed by Sanger sequencing after the RT-PCR product was subcloned into the pCR2.1-TOPO TA cloning vector (Thermo Fisher Scientific). The murine *Foxn1* cDNA was subcloned into the pCMV-FLAG-vector (MilliporeSigma) using the Bgl II/Kpn I restriction enzyme cloning sites. Site-directed mutagenesis was performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The human *FOXNI* mutations were introduced into the murine equivalent location with complementary oligonucleotide primers, which are listed in Supplemental Table 5. All mutated sequences were confirmed with DNA sequencing. Exon 8 from genomic DNA obtained from Pt. 2 was prepared and subcloned by PCR reactions using LA-Taq (Takara). The PCR reactions were resolved on agarose gels, and a 479-bp fragment was isolated and subcloned into pCR2.1 using the TOPO-TA Cloning System (Thermo Fisher Scientific). Eighteen independent clones were expanded and used for sequencing with T7 primers.

**Thymocyte and EC preparations.** Thymocyte and peripheral T cell populations were processed and stained for flow cytometric analyses as previously described (53, 54). TECs were isolated from individual thymic lobes by digestion in Liberase (Roche) in the presence of DNase I (Roche) as described previously (55). The cells were stained with antibodies against CD45 (Tonbo Scientific), MHC CII (I-A/I-E) (Tonbo Scientific), EpCAM (eBioscience), BP-1 (eBioscience), and UEA-1 (Vector Laboratories). Samples were analyzed on a FACSCanto II Flow Cytometer (BD Bioscience). FlowJo software (Tree Star) was used to analyze the flow data. TEC subsets were analyzed by selection of CD45<sup>+</sup>EpCAM<sup>+</sup>MHCII<sup>+</sup> cells with either UEA1<sup>+</sup>BP1<sup>-</sup> for medullary TECs or BP1<sup>+</sup>UEA1<sup>-</sup> for cortical TECs. MHC CII<sup>hi</sup> and MHC CII<sup>lo</sup> cells were used to discriminate between the 2 cortical and 2 medullary TEC subsets. Thymocyte subsets and peripheral T cells were analyzed for cell-surface expression of various proteins including CD3, CD4, CD8, CD11b, CD11c, CD19, CD25, CD44, CD45, CD69, B220, NK1.1,  $\alpha\beta$  TCR,  $\gamma\delta$  TCR, and Ter119 (see Supplemental Table 4 for antibody sources).

**RNA isolation and analysis.** RNA was isolated from adult thymic tissues and P4 skin with miRNAeasy kits (QIAGEN). The tissues were

initially homogenized with a Dounce homogenizer in the presence of QIAzol (QIAGEN). For embryonic thymi, a miRVANA RNA Isolation Kit (Ambion, Thermo Fisher Scientific) was used to isolate the RNA. Contaminating DNA from all the RNA preparations was eliminated by DNase I digestion (Ambion, Thermo Fisher Scientific) using in-column digestion and/or DNase treatment followed by purification with an RNA clean-up step (RNA-5 Quick and Clean, Zymo Research Inc.). cDNA was generated with 100 ng to 1  $\mu$ g RNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Random priming was used for reverse transcription. qRT-PCR was performed with 100 ng cDNA using SYBR Green (Thermo Fisher Scientific). The various PCR reactions and conditions were performed as described previously (56). For gene expression comparisons, the Affymetrix Murine Clariom S mouse array was used, which focuses on 20,000 well annotated genes (Thermo Fisher Scientific). The data on comparisons of the differentially expressed transcripts are available in the Gene Expression Ontology (GES) database (GES 134458; <https://bioportal.bioontology.org/ontologies/GEXO>).

**IHC and Western blot analysis.** Thymic tissue was fixed and embedded in paraffin. H&E staining was performed as standard protocol, and tissue was imaged on an Axiovert 200M inverted fluorescence microscope. For immunofluorescence staining, sections were incubated with rabbit anti-cytokeratin 5 (1:100, Abcam) and mouse anti-cytokeratin 8 (1:100, BioLegend) at 4°C overnight. The next day, sections were washed with PBS and stained with goat anti-mouse AF488 and donkey anti-rabbit AF555 secondary antibody (1:200, Invitrogen, Thermo Fisher Scientific). Tissues were then stained with DAPI and mounted with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific). Images were taken on a Leica confocal microscope. Western blotting was performed as described elsewhere using RIPA lysis procedures with antibodies against Foxn1, GAPDH, and the FLAG epitope listed in Supplemental Table 4 (57).

**Transfections and luciferase reporter assays.** A luciferase reporter containing the promoter of the *Psmbl1* gene was provided by S. Zuklys and G. Holländer (University of Oxford, Oxford, United Kingdom) (2). The *Psmbl1* luciferase reporter construct (0.5  $\mu$ g) was cotransfected into HEK 293T cells ( $2.5 \times 10^5$  cells/well) together with pCMV-FLAG (0.5  $\mu$ g) expression vectors containing *Foxn1* WT or mutants, using Fugene 6 Reagent (Promega). A separate construct containing  $\beta$ -gal (0.1  $\mu$ g) was included in the transfections to normalize each well for transfection efficiency. Forty-eight hours after transfection, the cells were harvested and the luciferase activity measured using a luciferase assay kit (Promega). Luciferase activity was normalized to  $\beta$ -gal activity, which was used as an internal control.

**Statistics.** Statistical analyses were performed using GraphPad Prism software, versions 7.0d and 8.2 (GraphPad Software). A *P* value of less than 0.05 was considered statistically significant. For Figure 2D, Figure 3D, and Figure 4D, a Brown-Forsythe and Welch's 1-way ANOVA was applied instead of an ordinary 1-way ANOVA, since the variances were quite extreme, because the various knockin mouse groups had extremely low cell numbers and percentages relative to the control *Foxn1*<sup>WT/WT</sup> line (ordinary ANOVA assumes equal variances). For Figure 6, C and D, a normal 1-way ANOVA analysis was applied. Standard Student's *t* tests were used for data analysis in Figure 5F and Figure 7, D and E.

**Study approval.** The IRB of UT Southwestern Medical Center approved this study (approval nos. 072010-009 and 112010-013). MLM, GTP, and TRY acquired a limited set of data on different

*FOXN1* patients in the United States. Consent for sequencing of DNA from Pt. 2 was obtained. Sequence information on deidentified Pts. 3–16 were obtained under a protocol declared exempt by the IRB of the Duke University Health System. The data were forwarded by various clinicians throughout the United States. Animal experiments described in this work were approved by and conducted with oversight of the IACUC of UT Southwestern (APN nos. 2015-101247 and 2015-101163). Mice were housed in a specific pathogen-free facility at UT Southwestern Medical Center. The *Foxn1*-targeted mice were developed entirely on a C57BL/6 background. Although more than 40 founders were screened for each construct, 2 independent mouse lines were expanded for each of the mutations generated by CRISPR-Cas: the *Foxn1*<sup>933</sup> mutations (Foxn1-933 no. 17 and Foxn1-933 no. 30) and the *Foxn1*<sup>1089</sup> mutations (Foxn1-1089 no. B4 and Foxn1-1089 no. B15). The mice are described further in Supplemental Table 4. The *Foxn1* mouse lines were crossed for 1 to 2 generations with C57BL/6 mice prior to intercrossing.

## Author contributions

MTDLM and CMS provided care for Pt. 1 and Pt. 2, respectively. MLM, GTP, and TRY acquired deidentified genetic data under an IRB-exempt protocol for Pt. 3–Pt. 9, who were found to have mutations in *FOXN1*. QD, LKH, MLM, MDLM, and NSCVO conceived the experiments. QD, LKH, FC, ID, PR, EM, MAK, and NSCVO performed the experiments. ID, PR, and SK analyzed the RNA-Seq and array data. QD, LKH, FC, PR, ID, GTP, TRY, MLM, MTDLM, CAW, and NSCVO analyzed the data. QD, MDLM, and NSCVO wrote the manuscript. MLM and CMS reviewed the manuscript.

## Acknowledgments

We would like to thank Angela Mobley and Kayla Lopez from the flow cytometry core at UT Southwestern Medical Center for assistance with TEC sorting and flow analyses. We appreciate the suggestions and help provided by members of the van Oers laboratory. We are thankful for the statistical analysis that was suggested and/or provided by Lindsay Cowell (Department of Bioinformatics, UT Southwestern Medical Center). Caitlyn Braisch from Ondine Cleaver's laboratory at UT Southwestern Medical Center provided image acquisition assistance. We are grateful for the advice provided by Dong-Ming Su (University of North Texas Health Sciences Center) and Nancy Manley (Department of Genetics, University of Georgia). James Richardson, John Shelton, and staff from the Cardiology Core of UT Southwestern Medical Center provided help with thymic tissue and skin processing. The various *Foxn1*-targeted mice were generated with the help of Robert Hammer of the Transgenic and Knockout Core at UT Southwestern Medical Center. Saliu Züklys and Georg Holländer (University Children's Hospital and University of Basel, Basel, Switzerland) provided the  $\beta$ 5t transcriptional reporter construct. We further acknowledge the following physicians who provided genetic and clinical data on deidentified individuals with diverse *FOXN1* mutations. Patient information was provided to M. Louise Markert at Duke University (Durham, North Carolina, USA). The physicians included Jennifer Heimall (Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA); Elena Perez (Allergy Associates of the Palm Beaches, North Palm Beach Florida, USA); John Bohnsack and Karin Chen (University of Utah Health, Salt

Lake City, Utah, USA); Challice Bonifant (C.S. Mott Children's Hospital, Ann Arbor, Michigan, USA); Hana Niebur (Children's Hospital and Medical Center, Omaha, Nebraska, USA); Jordan Abbott and Erwin W. Gelfand (National Jewish Health, Denver, Colorado, USA); Melissa E. Elder (University of Florida, Gainesville, Florida, USA); Lisa Forbes and Jacob J.H. Bleesing (University of Cincinnati, Cincinnati, Ohio, USA); David Buchbinder (Children's Hospital of Orange County, Orange, California, USA); Melanie Hankewicz (Hackensack Meridian, Hackensack, New Jersey, USA); Chaim Roifman (Sick Kids, Toronto, Canada); Evan B. Shereck (Oregon Health and Science University, Portland, Oregon, USA); Megan Cooper (St. Louis Children's Hospital, St. Louis, Missouri, USA); Lisa Bartnikas (Boston Children's Hospital, Boston, Massachusetts, USA); Rebecca H. Buckley (Duke University Medical Center, Durham, North Carolina, USA); Jennifer Leiding (University of South Florida, Saint Petersburg, Florida, USA); Anthony Hayward (Brown University, Providence, Rhode Island, USA); Benjamin T. Prince (Nationwide Children's Hospi-

tal, Columbus, Ohio, USA); Neena Kapoor (Children's Hospital of Los Angeles, Los Angeles, California, USA); Mark T. Vander Lugt (C.S. Mott Children's Hospital, Ann Arbor, Michigan, USA); and Tory Quigg (Methodist Children's Hospital, San Antonio, Texas, USA). Our work was supported in part by grants from the NIH (R01 AI114523 and R21 AI144140, to NSCVO); Beecherl funds from the Department of Immunology at UT Southwestern Medical Center (to NSCVO); and the Jeffrey Modell Foundation (to MDLM and CAW). Our work was also supported, in part, by grants from the NIH R01 (R01 AI114523, R21 AI144140 NSCVO), and the Jeffrey Modell Foundation (MDLM).

Address correspondence to: Nicolai S.C. van Oers, NA2.200, 6000 Harry Hines Boulevard, Dallas, Texas, 75390-9093, USA. Phone: 214.648.1236; Email: Nicolai.vanoers@utsouthwestern.edu.

QD's present address is: Harbour Biomed, Newton, Massachusetts, USA.

- Vaidya HJ, Briones Leon A, Blackburn CC. FOXP1 in thymus organogenesis and development. *Eur J Immunol*. 2016;46(8):1826-1837.
- Žuklys S, et al. Foxn1 regulates key target genes essential for T cell development in postnatal thymic epithelial cells. *Nat Immunol*. 2016;17(10):1206-1215.
- Gordon J, Manley NR. Mechanisms of thymus organogenesis and morphogenesis. *Development*. 2011;138(18):3865-3878.
- Anderson G, Takahama Y. Thymic epithelial cells: working class heroes for T cell development and repertoire selection. *Trends Immunol*. 2012;33(6):256-263.
- van der Spek J, Groenwold RH, van der Burg M, van Montfrans JM. TREC based newborn screening for severe combined immunodeficiency disease: a systematic review. *J Clin Immunol*. 2015;35(4):416-430.
- Abramson J, Anderson G. Thymic epithelial cells. *Annu Rev Immunol*. 2017;35:85-118.
- Satoh R, et al. Requirement of Stat3 signaling in the postnatal development of thymic medullary epithelial cells. *PLoS Genet*. 2016;12(1):e1005776.
- Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D. The cellular mechanism of Aire control of T cell tolerance. *Immunity*. 2005;23(2):227-239.
- Takaba H, et al. Fezf2 orchestrates a thymic program of self-antigen expression for immune tolerance. *Cell*. 2015;163(4):975-987.
- Aschenbrenner K, et al. Selection of Foxp3<sup>+</sup> regulatory T cells specific for self antigen expressed and presented by Aire<sup>+</sup> medullary thymic epithelial cells. *Nat Immunol*. 2007;8(4):351-358.
- Liu Z, Gerner MY, Van Panhuys N, Levine AG, Rudensky AY, Germain RN. Immune homeostasis enforced by co-localized effector and regulatory T cells. *Nature*. 2015;528(7581):225-230.
- Nehls M, Pfeifer D, Schorpp M, Hedrich H, Boehm T. New member of the winged-helix protein family disrupted in mouse and rat nude mutations. *Nature*. 1994;372(6501):103-107.
- Hannenhalli S, Kaestner KH. The evolution of Fox genes and their role in development and disease. *Nat Rev Genet*. 2009;10(4):233-240.
- Gajiwala KS, et al. Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding. *Nature*. 2000;403(6772):916-921.
- Bajoghli B, et al. A thymus candidate in lampreys. *Nature*. 2011;470(7332):90-94.
- Swann JB, et al. Conversion of the thymus into a bipotent lymphoid organ by replacement of FOXP1 with its paralog, FOXP4. *Cell Rep*. 2014;8(4):1184-1197.
- Newman JA, et al. The structural basis for forkhead box family specificity revealed by the crystal structure of human FOXP1 in complex with DNA. *bioRxiv*. <https://doi.org/10.1101/428011>. Accessed September 26, 2018. Accessed August 22, 2019.
- Schüddekopf K, Schorpp M, Boehm T. The whn transcription factor encoded by the nude locus contains an evolutionarily conserved and functionally indispensable activation domain. *Proc Natl Acad Sci U S A*. 1996;93(18):9661-9664.
- Schlake T, Schorpp M, Nehls M, Boehm T. The nude gene encodes a sequence-specific DNA binding protein with homologs in organisms that lack an anticipatory immune system. *Proc Natl Acad Sci U S A*. 1997;94(8):3842-3847.
- Flanagan SP. 'Nude', a new hairless gene with pleiotropic effects in the mouse. *Genet Res*. 1966;8(3):295-309.
- Wortis HH, Nehlsen S, Owen JJ. Abnormal development of the thymus in "nude" mice. *J Exp Med*. 1971;134(3 Pt 1):681-692.
- Radha Rama Devi A, Panday NN, Naushad SM. FOXP1 Italian founder mutation in Indian family: Implications in prenatal diagnosis. *Gene*. 2017;627:222-225.
- Chou J, Massaad MJ, Wakim RH, Bainter W, Dbaibo G, Geha RS. A novel mutation in FOXP1 resulting in SCID: a case report and literature review. *Clin Immunol*. 2014;155(1):30-32.
- Vigliano I, et al. FOXP1 mutation abrogates prenatal T-cell development in humans. *J Med Genet*. 2011;48(6):413-416.
- Pignata C, et al. Congenital Alopecia and nail dystrophy associated with severe functional T-cell immunodeficiency in two sibs. *Am J Med Genet*. 1996;65(2):167-170.
- Li B, Li J, Devlin BH, Markert ML. Thymic microenvironment reconstitution after postnatal human thymus transplantation. *Clin Immunol*. 2011;140(3):244-259.
- Abitbol M, Bossé P, Thomas A, Tiret L. A deletion in FOXP1 is associated with a syndrome characterized by congenital hypotrichosis and short life expectancy in Birman cats. *PLoS One*. 2015;10(3):e0120668.
- Romano R, et al. FOXP1: A master regulator gene of thymic epithelial development program. *Front Immunol*. 2013;4:187.
- Zweier C, Sticht H, Aydin-Yaylagül I, Campbell CE, Rauch A. Human TBX1 missense mutations cause gain of function resulting in the same phenotype as 22q11.2 deletions. *Am J Hum Genet*. 2007;80(3):510-517.
- Yagi H, et al. Role of TBX1 in human del22q11.2 syndrome. *Lancet*. 2003;362(9393):1366-1373.
- Paganini I, et al. A novel PAX1 null homozygous mutation in autosomal recessive otofaciocervical syndrome associated with severe combined immunodeficiency. *Clin Genet*. 2017;92(6):664-668.
- Pohl E, et al. A hypofunctional PAX1 mutation causes autosomal recessively inherited otofaciocervical syndrome. *Hum Genet*. 2013;132(11):1311-1320.
- Gennery AR, et al. Mutations in CHD7 in patients with CHARGE syndrome cause T-B + natural killer cell + severe combined immune deficiency and may cause Omenn-like syndrome. *Clin Exp Immunol*. 2008;153(1):75-80.
- Liu N, et al. Functional variants in TBX2 are associated with a syndromic cardiovascular and skeletal developmental disorder. *Hum Mol Genet*. 2018;27(14):2454-2465.
- Morsheimer M, Brown Whitehorn TF, Heimall J, Sullivan KE. The immune deficiency of chromosome 22q11.2 deletion syndrome. *Am J Med Genet A*. 2017;173(9):2366-2372.

36. Kwan A, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. *JAMA*. 2014;312(7):729-738.
37. Shearer WT, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. *J Allergy Clin Immunol*. 2003;112(5):973-980.
38. Cordier AC, Haumont SM. Development of thymus, parathyroids, and ultimobranchial bodies in NMRI and nude mice. *Am J Anat*. 1980;157(3):227-263.
39. Uddin MM, et al. Foxn1- $\beta$ 5t transcriptional axis controls CD8<sup>+</sup> T-cell production in the thymus. *Nat Commun*. 2017;8:14419.
40. Johns SA, Soullier S, Rashbass P, Cunliffe VT. Foxn1 is required for tissue assembly and desmosomal cadherin expression in the hair shaft. *Dev Dyn*. 2005;232(4):1062-1068.
41. Farley AM, et al. Dynamics of thymus organogenesis and colonization in early human development. *Development*. 2013;140(9):2015-2026.
42. Chen L, Xiao S, Manley NR. Foxn1 is required to maintain the postnatal thymic microenvironment in a dosage-sensitive manner. *Blood*. 2009;113(3):567-574.
43. Zook EC, et al. Overexpression of Foxn1 attenuates age-associated thymic involution and prevents the expansion of peripheral CD4 memory T cells. *Blood*. 2011;118(22):5723-5731.
44. Sun L, Guo J, Brown R, Amagai T, Zhao Y, Su DM. Declining expression of a single epithelial cell-autonomous gene accelerates age-related thymic involution. *Aging Cell*. 2010;9(3):347-357.
45. Bredenkamp N, Nowell CS, Blackburn CC. Regeneration of the aged thymus by a single transcription factor. *Development*. 2014;141(8):1627-1637.
46. Potter CS, et al. The nude mutant gene Foxn1 is a HOXC13 regulatory target during hair follicle and nail differentiation. *J Invest Dermatol*. 2011;131(4):828-837.
47. Su DM, Navarre S, Oh WJ, Condie BG, Manley NR. A domain of Foxn1 required for crosstalk-dependent thymic epithelial cell differentiation. *Nat Immunol*. 2003;4(11):1128-1135.
48. Gui J, Mustachio LM, Su DM, Craig RW. Thymus size and age-related thymic involution: early programming, sexual dimorphism, progenitors and stroma. *Aging Dis*. 2012;3(3):280-290.
49. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. *Annu Rev Immunol*. 2000;18:529-560.
50. Belkaya S, et al. Dynamic modulation of thymic microRNAs in response to stress. *PLoS One*. 2011;6(11):e27580.
51. Markert ML, et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. *Blood*. 2007;109(10):4539-4547.
52. Markert ML, et al. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. *Blood*. 2003;102(3):1121-1130.
53. Belkaya S, Murray SE, Eitson JL, de la Morena MT, Forman JA, van Oers NS. Transgenic expression of microRNA-185 causes a developmental arrest of T cells by targeting multiple genes including Mzb1. *J Biol Chem*. 2013;288(42):30752-30762.
54. Hoover AR, et al. MicroRNA-205 maintains T cell development following stress by regulating forkhead box N1 and selected chemokines. *J Biol Chem*. 2016;291(44):23237-23247.
55. Williams KM, Mella H, Lucas PJ, Williams JA, Telford W, Gress RE. Single cell analysis of complex thymus stromal cell populations: rapid thymic epithelia preparation characterizes radiation injury. *Clin Transl Sci*. 2009;2(4):279-285.
56. Du Q, et al. MIR205HG is a long noncoding RNA that regulates growth hormone and prolactin production in the anterior pituitary. *Dev Cell*. 2019;49(4):618-631.e5.
57. DeFord-Watts LM, et al. The CD3 zeta subunit contains a phosphoinositide-binding motif that is required for the stable accumulation of TCR-CD3 complex at the immunological synapse. *J Immunol*. 2011;186(12):6839-6847.